1144080-35-2 Usage
Uses
Used in Pharmaceutical Industry:
3-(6-chloro-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyriMidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane is used as a potential pharmaceutical candidate for [specific application reason, if known]. Its unique chemical structure, including the pyrazolo[3,4-d]pyrimidine and oxabicyclooctane rings, as well as the chloro substituent and 1,4-dioxaspiro[4.5]decan-8-yl group, may contribute to its potential therapeutic effects.
Used in Biological Research:
In the field of biological research, 3-(6-chloro-1-(1,4-dioxaspiro[4.5]decan-8-yl)-1H-pyrazolo[3,4-d]pyriMidin-4-yl)-8-oxa-3-azabicyclo[3.2.1]octane serves as a valuable compound for studying [specific research area, if known]. Its complex structure allows scientists to explore various aspects of its interactions with biological systems, potentially leading to new insights and discoveries in the field.
Check Digit Verification of cas no
The CAS Registry Mumber 1144080-35-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,4,4,0,8 and 0 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1144080-35:
(9*1)+(8*1)+(7*4)+(6*4)+(5*0)+(4*8)+(3*0)+(2*3)+(1*5)=112
112 % 10 = 2
So 1144080-35-2 is a valid CAS Registry Number.
1144080-35-2Relevant academic research and scientific papers
Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent
Curran, Kevin J.,Verheijen, Jeroen C.,Kaplan, Joshua,Richard, David J.,Toral-Barza, Lourdes,Hollander, Irwin,Lucas, Judy,Ayral-Kaloustian, Semiramis,Yu, Ker,Zask, Arie
scheme or table, p. 1440 - 1444 (2010/07/06)
A series of pyrazolopyrimidine mammalian Target Of Rapamycin (mTOR) inhibitors with various substituents at the 1-position have been prepared, resulting in compounds with excellent potency, selectivity and microsomal stability. Combination of a 1-cyclohexyl ketal group with a 2,6-ethylene bridged morpholine in the 4-position and a ureidophenyl group in the 6-positon resulted in compound 8a, that selectively suppressed key mTOR biomarkers in vivo for at least 8 h following iv administration and showed excellent oral activity in a xenograft tumor model.
